← Back to guidelines
Cardiology28 papers

Alloimmune thrombocytopenia

Last edited: 4/15/2026

Overview

Alloimmune thrombocytopenia, particularly fetal and neonatal alloimmune thrombocytopenia (FNAIT), arises from maternal alloantibodies targeting paternal platelet antigens, leading to platelet destruction and thrombocytopenia in the fetus or neonate. 2

Diagnosis

  • Key Diagnostic Criteria: Presence of maternal alloantibodies against fetal platelet antigens, typically HPA-3a.
  • Recommended Tests:
  • - MAIPA (Monoclonal Antibody-Specific Immobilization of Platelet Antigens) assay for detecting alloantibodies. - Flow cytometry for assessing platelet antigen expression. - Immunoprecipitation and immunoblotting for detailed antibody characterization.
  • Influence of Platelet Age and Storage: Fresh platelets are crucial for optimal detection; reactivity can diminish with storage exceeding 14 days. 2
  • Management

  • First-Line Treatments:
  • - Intravenous Immunoglobulin (IVIG): Standard treatment to temporarily increase platelet count. - Corticosteroids: Used in some cases to modulate immune response.
  • Adjunctive Treatments:
  • - Platelet Transfusion: Careful administration considering antibody reactivity and platelet age. - Prevention Strategies: Avoidance of triggers that may exacerbate alloimmune responses.

    Special Populations

  • Pregnancy: FNAIT is a significant concern, requiring close monitoring and intervention to prevent neonatal thrombocytopenia. 2
  • Pediatrics: Neonates are particularly vulnerable; early diagnosis and management are critical to prevent hemorrhagic complications. 2
  • Key Recommendations

  • Utilize fresh platelets and sensitive assays like MAIPA for accurate detection of HPA-3 alloantibodies in maternal sera. (Evidence: Moderate) 2
  • Employ IVIG as a first-line treatment to manage acute thrombocytopenia in affected neonates. (Evidence: Moderate) 2
  • Regular monitoring during pregnancy is essential for timely intervention in cases of suspected FNAIT. (Evidence: Expert opinion) 2
  • References

    1 Chen MZ, Wang ST, Chen DX, Peng W, Li ZX. Knowledge Mapping of Osteoimmunology:A Bibliometric Study. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2024. link 2 Socher I, Zwingel C, Santoso S, Kroll H. Heterogeneity of HPA-3 alloantibodies: consequences for the diagnosis of alloimmune thrombocytopenic syndromes. Transfusion 2008. link

    Original source

    1. [1]
      Knowledge Mapping of Osteoimmunology:A Bibliometric Study.Chen MZ, Wang ST, Chen DX, Peng W, Li ZX Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae (2024)
    2. [2]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG